title: Treatment of human prostate tumors PC-3 and TSU-PR1 with standard and investigational agents in SCID mice.
abstract: Both the PC-3 and the TSU-PR1 prostate tumor models were found to be satisfactory for chemotherapeutic investigations in ICR-SCID mice. The 30 to 60 mg fragments implanted took in all mice (as judged by 100% takes in the controls of all experiments as well as the passage mice). The tumor volume doubling time was 4.0 days for PC-3 and 2.5 days for TSU-PR1. Nine agents were evaluated IV against early stage subcutaneous PC-3 tumors, with Nano-piposulfan being the only agent highly active (4.9 log kill). Three other agents were moderately active: Taxol (1.5 log kill), Cryptophycin-8 (1.6 log kill), Vinblastine (1.0 log kill). Five agents were inactive: VP-16, Adriamycin, CisDDPt, 5-FUra, and Cyclophosphamide. Ten agents were evaluated IV against early stage subcutaneous TSU-PR1 tumors. Three agents were highly active, producing > 6 log kill and cures: Taxol (5/5 cures), Cryptophycin-8 (5/5 cures), Vinblastine (2/4 cures). Two other agents were moderately active: Nano-piposulfan (1.2 log kill), and Cyclophosphamide (1.1 log kill). Five agents were inactive: VP-16, Adriamycin, CisDDPt, 5-FUra, and BCNU. In part, activity was determined by the ability of the SCID mice to tolerate meaningful dosages of the agents. Agents producing granulocyte toxicity (e.g., Adriamycin) were poorly tolerated and appeared less active than expected. Vinblastine, producing little or no granulocyte toxicity was very well tolerated and appeared to be more active than expected.
authors.affiliation: Department of Internal Medicine, Wayne State University School of Medicine, Detroit, USA.
authors.forename: L
authors.initials: L
authors.lastname: Polin
authors.forename: F
authors.initials: F
authors.lastname: Valeriote
authors.forename: K
authors.initials: K
authors.lastname: White
authors.forename: C
authors.initials: C
authors.lastname: Panchapor
authors.forename: S
authors.initials: S
authors.lastname: Pugh
authors.forename: J
authors.initials: J
authors.lastname: Knight
authors.forename: P
authors.initials: P
authors.lastname: LoRusso
authors.forename: M
authors.initials: M
authors.lastname: Hussain
authors.forename: E
authors.initials: E
authors.lastname: Liversidge
authors.forename: N
authors.initials: N
authors.lastname: Peltier
authors.forename: T
authors.initials: T
authors.lastname: Golakoti
authors.forename: G
authors.initials: G
authors.lastname: Patterson
authors.forename: R
authors.initials: R
authors.lastname: Moore
authors.forename: T H
authors.initials: TH
authors.lastname: Corbett
mesh_terms: D000368:Aged; D000818:Animals; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D047630:Depsipeptides; D015507:Drugs, Investigational / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D007769:Lactams / Q000627:therapeutic use; D007783:Lactones / Q000627:therapeutic use; D008297:Male; D051379:Mice; D008819:Mice, Nude; D016513:Mice, SCID; D008875:Middle Aged; D017239:Paclitaxel / Q000627:therapeutic use; D010879:Piperazines / Q000627:therapeutic use; D011471:Prostatic Neoplasms / Q000188:drug therapy*; D014747:Vinblastine / Q000627:therapeutic use
chemical_list: D000970:Antineoplastic Agents; D047630:Depsipeptides; D015507:Drugs, Investigational; D007769:Lactams; D007783:Lactones; D010879:Piperazines; C107304:cryptophycin 8; D014747:Vinblastine; D017239:Paclitaxel; C107303:piposulfan